Tenax Therapeutics is trading at $1.50 (10.29% up) with no verified company-specific news explaining the current upward move.
- The stock is trading higher compared to its October 16 close of $1.36.
- A major recent development involves an October 18 report that the Phase 3 LEVEL trial missed its primary and key secondary endpoints, which previously triggered a severe selloff.
- The connection between the recent trial failure and today's price action remains unclear.